ERBB2 and breast cancer: (136) found that high levels of autoantibodies against tumor-infiltrating lymphocytes (TILs) and p53 were associated with better prognosis in HER2-positive breast cancer patients, while autoantibodies against MSH2, EZR, PGK1, VCL and ANXA2 were associated with poorer pancreatic cancer patient outcomes (137).